This content is for members only
This content is for members only
On Wednesday, May 27, Zynerba (NASDAQ:ZYNE) reported positive data from its phase II trial testing its cannabinoid drug Zygel to treat pediatric and adolescent patients with autism spectrum disorder (ASD). The stock rose in Wednesday morning trading to $6.30 per […]
Harpoon Therapeutics (NASDAQ:HARP), a biotechnology company developing an antibody platform to treat different forms of cancer, climbed approximately 20% in the last 10 minutes of trading on Friday, May 29, to close at $21.76 per share. Earlier in the day, […]
This content is for members only
Avadel Pharmaceuticals plc (NASDAQ:AVDL) recently announced positive phase III trial results for its drug FT218 to treat excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. SanaCurrents forecast in September 2019 that Avadel’s pivotal phase III trial, called REST-ON, […]
This content is for members only
This content is for members only